NO304151B1 - Oksydert peptid som er immunreaktivt med antistoffer mot et naturlig retrovirus-protein, fremgangsmÕte for fremstilling av og anvendelse av en peptidbelagt fast fase - Google Patents

Oksydert peptid som er immunreaktivt med antistoffer mot et naturlig retrovirus-protein, fremgangsmÕte for fremstilling av og anvendelse av en peptidbelagt fast fase Download PDF

Info

Publication number: NO304151B1
Authority: NO; Norway
Prior art keywords: peptide; solid phase; peptides; cys; hiv
Prior art date: 1989-06-02

Application number

NO914725A

Other languages

English (en)

Norwegian (no)

Other versions

NO914725L (no

NO914725D0 (no

Inventor

James Blake

Carol-Ann Cole

Patrick Coleman

Nobuo Monji

John P Montana

Original Assignee

Genetic Systems Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-02

Filing date

1991-11-29

Publication date

1998-11-02

1991-11-29 Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp

1991-11-29 Publication of NO914725D0 publication Critical patent/NO914725D0/no

1992-01-29 Publication of NO914725L publication Critical patent/NO914725L/no

1998-11-02 Publication of NO304151B1 publication Critical patent/NO304151B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 251
239000007790 solid phase Substances 0.000 title claims description 32
238000000034 method Methods 0.000 title claims description 27
108010013377 Retroviridae Proteins Proteins 0.000 title claims description 7
208000031886 HIV Infections Diseases 0.000 claims abstract description 22
241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 22
239000000427 antigen Substances 0.000 claims abstract description 16
102000036639 antigens Human genes 0.000 claims abstract description 16
108091007433 antigens Proteins 0.000 claims abstract description 16
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 14
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims abstract description 13
241000714259 Human T-lymphotropic virus 2 Species 0.000 claims abstract description 11
DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims abstract description 9
241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract 2
150000001413 amino acids Chemical class 0.000 claims description 31
-1 Cys amino acids Chemical class 0.000 claims description 24
239000004816 latex Substances 0.000 claims description 24
229920000126 latex Polymers 0.000 claims description 24
238000003018 immunoassay Methods 0.000 claims description 20
230000002441 reversible effect Effects 0.000 claims description 20
230000015572 biosynthetic process Effects 0.000 claims description 18
238000001514 detection method Methods 0.000 claims description 16
230000027455 binding Effects 0.000 claims description 14
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
230000003647 oxidation Effects 0.000 claims description 13
238000007254 oxidation reaction Methods 0.000 claims description 13
230000001900 immune effect Effects 0.000 claims description 11
230000001590 oxidative effect Effects 0.000 claims description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
238000003786 synthesis reaction Methods 0.000 claims description 8
DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 claims description 7
238000011002 quantification Methods 0.000 claims description 6
125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
238000003776 cleavage reaction Methods 0.000 claims description 5
238000001914 filtration Methods 0.000 claims description 5
230000007017 scission Effects 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
239000007795 chemical reaction product Substances 0.000 claims description 4
239000011541 reaction mixture Substances 0.000 claims description 4
239000004677 Nylon Substances 0.000 claims description 3
239000004793 Polystyrene Substances 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 3
229920002313 fluoropolymer Polymers 0.000 claims description 3
230000036046 immunoreaction Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229920001778 nylon Polymers 0.000 claims description 3
229920002401 polyacrylamide Polymers 0.000 claims description 3
229920002223 polystyrene Polymers 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000012472 biological sample Substances 0.000 claims 3
230000002194 synthesizing effect Effects 0.000 claims 2
230000003100 immobilizing effect Effects 0.000 claims 1
239000003223 protective agent Substances 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 63
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract description 18
235000018102 proteins Nutrition 0.000 abstract description 17
102000004169 proteins and genes Human genes 0.000 abstract description 17
108090000623 proteins and genes Proteins 0.000 abstract description 17
241001430294 unidentified retrovirus Species 0.000 abstract description 6
239000011324 bead Substances 0.000 description 57
229940024606 amino acid Drugs 0.000 description 31
235000001014 amino acid Nutrition 0.000 description 31
239000000463 material Substances 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000000523 sample Substances 0.000 description 16
230000009257 reactivity Effects 0.000 description 15
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
239000012528 membrane Substances 0.000 description 14
241000725303 Human immunodeficiency virus Species 0.000 description 13
241000700605 Viruses Species 0.000 description 13
239000000243 solution Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
238000002965 ELISA Methods 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
238000003556 assay Methods 0.000 description 12
239000012153 distilled water Substances 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
238000012360 testing method Methods 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
238000011161 development Methods 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000006166 lysate Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000007995 HEPES buffer Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
238000002372 labelling Methods 0.000 description 7
239000011347 resin Substances 0.000 description 7
229920005989 resin Polymers 0.000 description 7
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
238000002156 mixing Methods 0.000 description 6
238000001179 sorption measurement Methods 0.000 description 6
239000000758 substrate Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
241000283707 Capra Species 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
101800000385 Transmembrane protein Proteins 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
238000001262 western blot Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108010038807 Oligopeptides Proteins 0.000 description 4
102000015636 Oligopeptides Human genes 0.000 description 4
101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
239000010839 body fluid Substances 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
230000009260 cross reactivity Effects 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
239000013642 negative control Substances 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000011534 incubation Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000000047 product Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
108091007466 transmembrane glycoproteins Proteins 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
FDEOPFSXGJBPRR-BYPYZUCNSA-N (2r)-2-azaniumyl-3-(ethylcarbamoylsulfanyl)propanoate Chemical compound CCNC(=O)SC[C@H]([NH3+])C([O-])=O FDEOPFSXGJBPRR-BYPYZUCNSA-N 0.000 description 2
DPYOGHWMKHFWKG-ZETCQYMHSA-N (2r)-3-(ethylcarbamoylsulfanyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CCNC(=O)SC[C@@H](C(O)=O)NC(=O)OC(C)(C)C DPYOGHWMKHFWKG-ZETCQYMHSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
239000013024 dilution buffer Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000012898 sample dilution Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910001961 silver nitrate Inorganic materials 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
150000003573 thiols Chemical group 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
LKUOJDGRNKVVFF-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C(=O)C=CC1=O LKUOJDGRNKVVFF-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
NMHGKQRBLJOZEL-UHFFFAOYSA-N 4-methylbenzenecarbodithioic acid Chemical compound CC1=CC=C(C(S)=S)C=C1 NMHGKQRBLJOZEL-UHFFFAOYSA-N 0.000 description 1
IXPHOHNWDLRFJH-UHFFFAOYSA-N 6-amino-2-[[6-amino-2-[[6-amino-2-[[6-amino-2-(2,6-diaminohexanoylamino)hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCCC(N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(O)=O IXPHOHNWDLRFJH-UHFFFAOYSA-N 0.000 description 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102100033620 Calponin-1 Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101800005164 Peptide V Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241000183024 Populus tremula Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
239000012491 analyte Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000005081 chemiluminescent agent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000000694 effects Effects 0.000 description 1
WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
235000021190 leftovers Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
108010091617 pentalysine Proteins 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
CYFJIBWZIQDUSZ-UHFFFAOYSA-N thioglycine Chemical group NCC(S)=O CYFJIBWZIQDUSZ-UHFFFAOYSA-N 0.000 description 1
239000013638 trimer Substances 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Microbiology (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO914725A 1989-06-02 1991-11-29 Oksydert peptid som er immunreaktivt med antistoffer mot et naturlig retrovirus-protein, fremgangsmÕte for fremstilling av og anvendelse av en peptidbelagt fast fase NO304151B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36051389A	1989-06-02	1989-06-02
PCT/US1990/003148 WO1990015071A1 (en)	1989-06-02	1990-06-04	Cysteine thiol-protected peptides for use in immunoassays

Publications (3)

Publication Number	Publication Date
NO914725D0 NO914725D0 (no)	1991-11-29
NO914725L NO914725L (no)	1992-01-29
NO304151B1 true NO304151B1 (no)	1998-11-02

Family

ID=23418295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO914725A NO304151B1 (no)	1989-06-02	1991-11-29	Oksydert peptid som er immunreaktivt med antistoffer mot et naturlig retrovirus-protein, fremgangsmÕte for fremstilling av og anvendelse av en peptidbelagt fast fase

Country Status (12)

Country	Link
EP (1)	EP0474789B1 (de)
JP (1)	JP3404035B2 (de)
KR (1)	KR960013600B1 (de)
AT (1)	ATE162799T1 (de)
AU (1)	AU652919B2 (de)
CA (1)	CA2056381C (de)
DE (1)	DE69032009T2 (de)
DK (1)	DK0474789T3 (de)
ES (1)	ES2113860T3 (de)
FI (1)	FI102834B (de)
NO (1)	NO304151B1 (de)
WO (1)	WO1990015071A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6083504A (en) *	1989-08-24	2000-07-04	Bioclonetics Incorporated	Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1)
US5459060A (en) *	1989-08-24	1995-10-17	Bioclonetics Incorporated	Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
US6008044A (en) *	1989-08-24	1999-12-28	Bioclonetics	Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
DE69129207T2 (de) *	1990-01-16	1998-10-08	Orgenics Ltd	Peptide, von Virus-HIV-Hüllen-Glycoproteinen abstammend, deren Verwendung zum Nachweis einer Infektion dieser Viren und für die Impfung gegen AIDS
BR0015170A (pt) *	1999-10-27	2002-06-25	Innogenetics Nv	Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa
JP5182069B2 (ja) *	2008-12-24	2013-04-10	Ｊｎｃ株式会社	チオール基を有する刺激応答性磁性微粒子及びその利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4111924A (en) *	1976-01-05	1978-09-05	Takeda Chemical Industries, Ltd.	Method for removal of thiol-protecting groups
FR2525592B1 (de) *	1982-04-26	1984-09-14	Pasteur Institut
US4689398A (en) *	1984-06-20	1987-08-25	Ortho Diagnostic Systems Inc.	HTLV test using synthetic peptides
JPS63502904A (ja) *	1986-03-24	1988-10-27	オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン	合成ｈｔｌｖ−３ペプチド、その組成物及び用途
EP0247557B1 (de) *	1986-05-27	1994-04-20	F. Hoffmann-La Roche Ag	HTLV-III(LAV)Decke-Peptide
GB8828097D0 (en) *	1988-12-01	1989-01-05	Wellcome Found	Peptides

1990
- 1990-06-04 AU AU60532/90A patent/AU652919B2/en not_active Expired
- 1990-06-04 DE DE69032009T patent/DE69032009T2/de not_active Expired - Fee Related
- 1990-06-04 EP EP90911054A patent/EP0474789B1/de not_active Expired - Lifetime
- 1990-06-04 JP JP51045090A patent/JP3404035B2/ja not_active Expired - Lifetime
- 1990-06-04 WO PCT/US1990/003148 patent/WO1990015071A1/en not_active Ceased
- 1990-06-04 CA CA002056381A patent/CA2056381C/en not_active Expired - Lifetime
- 1990-06-04 DK DK90911054T patent/DK0474789T3/da active
- 1990-06-04 AT AT90911054T patent/ATE162799T1/de not_active IP Right Cessation
- 1990-06-04 KR KR1019910701744A patent/KR960013600B1/ko not_active Expired - Lifetime
- 1990-06-04 ES ES90911054T patent/ES2113860T3/es not_active Expired - Lifetime
1991
- 1991-11-29 NO NO914725A patent/NO304151B1/no not_active IP Right Cessation
- 1991-11-29 FI FI915649A patent/FI102834B/fi active

Also Published As

Publication number	Publication date
JP3404035B2 (ja)	2003-05-06
NO914725L (no)	1992-01-29
FI102834B1 (fi)	1999-02-26
CA2056381A1 (en)	1990-12-03
WO1990015071A1 (en)	1990-12-13
DE69032009D1 (de)	1998-03-05
FI102834B (fi)	1999-02-26
EP0474789A1 (de)	1992-03-18
DK0474789T3 (da)	1998-09-28
AU6053290A (en)	1991-01-07
AU652919B2 (en)	1994-09-15
JPH04505623A (ja)	1992-10-01
KR920701236A (ko)	1992-08-11
FI915649A0 (fi)	1991-11-29
ATE162799T1 (de)	1998-02-15
ES2113860T3 (es)	1998-05-16
KR960013600B1 (ko)	1996-10-09
NO914725D0 (no)	1991-11-29
EP0474789A4 (en)	1992-06-03
CA2056381C (en)	2000-08-22
DE69032009T2 (de)	1998-07-23
EP0474789B1 (de)	1998-01-28

Legal Events

Date	Code	Title	Description
2010-07-19	MK1K	Patent expired

Publication	Publication Date	Title
US4629783A (en)	1986-12-16	Synthetic antigen for the detection of AIDS-related disease
US6214539B1 (en)	2001-04-10	Synthetic antigen the detection of aids-related disease
US5439792A (en)	1995-08-08	Cysteine thiol-protected peptides for use in immunoassays
US5075211A (en)	1991-12-24	Synthetic antigen for the detection of AIDS-related disease
EP0247557A2 (de)	1987-12-02	HTLV-III(LAV)Decke-Peptide
US6322964B1 (en)	2001-11-27	Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies
CA1341436C (en)	2003-08-05	Synthetic antigens for the detection of aids-related disease caused by lav-2
AU652919B2 (en)	1994-09-15	Cysteine thiol-protected peptides for use in immunoassays
US7144697B1 (en)	2006-12-05	Synthetic antigen for the detection of antibodies immunoreactive with HIV virus
AU623949B2 (en)	1992-05-28	Synthetic peptide derivatives of gp41 glycoprotein of HIV
US20030054336A1 (en)	2003-03-20	Method for detecting hiv antibodies and antigens used to this end
AU597884C (en)	1994-03-17	Synthetic antigens for the detection of AIDS-related disease
US6130314A (en)	2000-10-10	Synthetic antigen for the detection of AIDS-related disease
CA2004287A1 (en)	1990-06-01	Peptides
NO173034B (no)	1993-07-05	Fremgangsmaate og peptider for paavisning av aids-relatert sykdom